Literature DB >> 28212694

Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.

Hiromitsu Tabata1, Akira Kuriyama2, Fusae Yamao1, Hiroshi Kitaguchi1, Katsuro Shindo1.   

Abstract

ABSTRACT: Suvorexant is a new insomnia drug, and it is generally safe and well tolerated. Here, we report a rare but potentially important adverse effect of suvorexant in a patient with Parkinson disease.
© 2017 American Academy of Sleep Medicine

Entities:  

Keywords:  Parkinson disease; REM sleep behavioral disorder; nightmare; polysomnography; suvorexant

Mesh：

Substances：

Year:  2017        PMID： 28212694      PMCID： PMC5406960          DOI： 10.5664/jcsm.6600

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


  5 in total

Review 1.  Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.

Authors:  Akira Kuriyama; Hiromitsu Tabata
Journal:  Sleep Med Rev       Date:  2016-10-28       Impact factor: 11.609

2.  Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

Authors:  Christopher D Cox; Michael J Breslin; David B Whitman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Anthony J Roecker; Swati P Mercer; Rodney A Bednar; Wei Lemaire; Joseph G Bruno; Duane R Reiss; C Meacham Harrell; Kathy L Murphy; Susan L Garson; Scott M Doran; Thomayant Prueksaritanont; Wayne B Anderson; Cuyue Tang; Shane Roller; Tamara D Cabalu; Donghui Cui; George D Hartman; Steven D Young; Ken S Koblan; Christopher J Winrow; John J Renger; Paul J Coleman
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

3.  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Authors:  Hong Sun; William P Kennedy; Darren Wilbraham; Nicole Lewis; Nicole Calder; Xiaodong Li; Junshui Ma; Ka Lai Yee; Susan Ermlich; Eric Mangin; Christopher Lines; Laura Rosen; Jeffrey Chodakewitz; Gail M Murphy
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

4.  REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease.

Authors:  J F Gagnon; M A Bédard; M L Fantini; D Petit; M Panisset; S Rompré; J Carrier; J Montplaisir
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

Review 5.  Profile of suvorexant in the management of insomnia.

Authors:  Eliza L Sutton
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162
  5 in total
  2 in total

1.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

Review 2.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.